Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure

Journal of Cardiac Surgery

Volumn 20, Issue 1, 2005, Pages 93-101

  Jayasankar, Vasant ^a   Woo, Y Joseph ^a   Pirolli, Timothy J ^a   Bish, Lawrence T ^a   Berry, Mark F ^a   Burdick, Jeffrey ^a   Gardner, Timothy J ^a   Sweeney, H Lee ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN BCL 2; SCATTER FACTOR; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFICACY; ENDOTHELIUM CELL; GENE EXPRESSION; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HEART VOLUME; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NICK END LABELING; NONHUMAN; RAT; RECEPTOR UPREGULATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANGIOGENESIS INDUCING AGENTS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; GENE TRANSFER TECHNIQUES; GENES, BCL-2; GENETIC VECTORS; HEART FAILURE, CONGESTIVE; HEPATOCYTE GROWTH FACTOR; IN SITU NICK-END LABELING; MALE; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, INBRED LEW; TREATMENT OUTCOME; UP-REGULATION;

EID: 12944265531     PISSN: 08860440     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0886-0440.2005.200373.x     Document Type: Article

References (38)

1. Krumholz HM, Chen YT, Wang Y, et al: Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J 2000;139:72-77.
2. American Heart Association, 2002. Heart and Stroke Statistical Update.
3. White HD, Norris RM, Brown MA, et al: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
4. Bialik S, Geenen DL, Sasson IE, et al: Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Invest 1997;100:1363-1372.
5. Scheubel RJ, Bartling B, Simm A, et al: Apoptotic pathway activation from mitochondria and death receptors without caspase-3 cleavage in failing human myocardium. J Am Coll Cardiol 2002;39:481-488.
6. Nakamura T, Nishizawa T, Hagiya M, et al: Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-443.
7. Bussolino F, Di Renzo MF, Ziche M, et al: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-641.
8. Grant DS, Kleinman HK, Goldberg ID, et al: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993;90:1927-1941.
9. Matsumoto K, Nakamura T: Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996;119: 591-600.
10. Kopp JB: Hepatocyte growth factor: Mesenchymal signal for epithelial homeostasis. Kidney Int 1998;54:1392-1393.
11. Gherardi E, Stoker M: Hepatocyte growth factor-scatter factor: Mitogen, motogen, and met. Cancer Cells 1991;3:227-232.
12. Ono K, Matsumori A, Shioi T, et al: Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997;95:2552-2558.
13. Ueda H, Sawa Y, Matsumoto K, et al: Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann Thorac Surg 1999;67:1726-1731.
14. Soeki T, Tamura Y, Sinohara H, et al: Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels 2000;15:105-111.
15. Yasuda S, Goto Y, Baba T, et al: Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol 2000;36:115-121.
16. Hayashi S, Morishita R, Nakamura S, et al: Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: Downregulation of HGF in response to hypoxia in vascular cells. Circulation 1999;100:11301-11308.
17. Bartlett RJ, Secore SL, Singer JT, et al: Long-term expression of a fluorescent reporter gene via direct injection of plasmid vector into mouse skeletal muscle: Comparison of human creatine kinase and CMV promoter expression levels in vivo. Cell Transp 1996;5:411-419.
18. Liu Y-H, Yang X-P, Mass O, et al: Chronic heart failure induced by coronary artery ligation in Lewis inbred rat. Am J Physiol 1997;272:H722-H727.
19. Hussong JW, Rodgers GM, Shami PJ: Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309-313.
20. Olivetti G, Ricci R, Beghi C: Response of the borderzone myocardial infarction in rats. Am J Pathol 1986;125:476-483.
21. Sharov VG, Sabbah HN, Shimoyama H, et al: Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996;148:141-149.
22. Yamamoto K, Morishita R, Hayashi S, et al: Contribution of Bcl-2, but not Bcl-xL and Bax, to antiapoptotic action of hepatocyte growth factor in hypoxia-conditioned human endothelial cells. Hypertension 2001;37:1341-1348.
23. Nakamura T, Mizuno S, Matsumoto K, et al: Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000;106:1511-1519.
24. Matsumori A, Furukawa Y, Hashimoto T, et al: Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochem Biophys Res Commun 1996;221:391-395.
25. Sato T, Yoshinouchi T, Sakamoto T, et al: Hepatocyte growth factor (HGF): A new biochemical marker for acute myocardial infarction. Heart Vessels 1997;12:241-246.
26. Heeschen C, Dimmeler S, Hamm CW, et al: Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 2003;107:524-530.
27. Cheng W, Kajstura J, Nitahara JA, et al: Programmed cell death contributes to ventricular remodeling after myocardial infarction in rats. Exp Cell Res 1996;226:316-327.
28. Page E, Polimein PI: Ultrastructural changes in the ischemic zone bordering experimental infarcts in rat left ventricles. Am J Pathol 1977;87:81-104.
29. Kramer CM, Lima JAC, Reichek N, et al: Regional differences in function within noninfarcted myocardium during left ventricular remodeling. Circulation 1993;88:1279-1288.
30. Wyatt HL, Forrester JS, daLuz PL, et al: Functional abnormalities in nonoccluded regions of myocardium after experimental coronary occlusion. Am J Cardiol 1976;37:366-372.
31. Olivetti G, Capasso JM, Meggs LG, et al: Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 1991;68:856-869.
32. Olivetti G, Abbi R, Quaini F, et al: Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-1141.
33. Sabbah HN: Apoptotic cell death in heart failure. Cardiovasc Res 2000;45:704-712.
34. Communal C, Sumandea M, de Tombe P, et al: Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 2002;99:6252-6256.
35. Aukrust P, Ueland T, Lien E, et al: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-382.
36. Blum A, Miller H: Pathophysiological role of cytokines in congestive heart failure. Ann Rev Med 2001;52:15-27.
37. Kubota T, McTiernan CF, Frye CS, et al: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997;81:627-635.
38. Bozkurt B, Kribbs SV, Clubb FJ Jr, et al: Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382-1391.